The total return over the past 12 months is +92.02% vs. +16.94% for the S&P 500. So far it's up +53.48% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +92.02% | (29.58%) | (35.20%) | (10.80%) | (0.81%) | N/A |
| Total Return CAGR | +92.02% | (29.58%) | (35.20%) | (10.80%) | (0.81%) | N/A |
| Revenue CAGR | +2.02% | (2.24%) | +8.52% | +5.87% | +19.22% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Pacific Biosciences of California, Inc. (PACB)
| Year | Start price | End price | PACB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.87 | $2.87 | +53.48% | +14.51% | +38.97% |
| 2025 | $1.83 | $1.87 | +2.19% | +17.72% | (15.53%) |
| 2024 | $9.81 | $1.83 | (81.35%) | +24.89% | (106.24%) |
| 2023 | $8.18 | $9.81 | +19.93% | +26.19% | (6.26%) |
| 2022 | $20.46 | $8.18 | (60.02%) | (18.17%) | (41.85%) |
| 2021 | $25.94 | $20.46 | (21.13%) | +28.74% | (49.87%) |
| 2020 | $5.14 | $25.94 | +404.67% | +18.37% | +386.30% |
| 2019 | $7.40 | $5.14 | (30.54%) | +31.22% | (61.76%) |
| 2018 | $2.64 | $7.40 | +180.30% | (4.56%) | +184.86% |
| 2017 | $3.80 | $2.64 | (30.53%) | +21.70% | (52.23%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
